0001628280-26-033429
SEC filingBicara Therapeutics reported a $56.2M net loss and $37.6M free cash outflow in Q1 FY2026 — a 52.6% YoY increase in loss magnitude — reflecting intensified clinical execution for ficerafusp alfa, while liquidity remains sufficient to fund operations into H1 2029 per management’s current plan.
Net loss for Q1 FY2026 was $56.2M, compared to $36.8M in Q1 FY2025 — a 52.6% increase in magnitude. This reflects the natural cost escalation associated with advancing therapeutic candidates into later stages of clinical development, where trials grow in size and duration. The company is currently progressing ficerafusp alfa, and therapeutic candidates at this stage generally incur higher development costs than those in earlier phases. Net cash used in operating activities was $37.5M, up from $28.1M in the prior-year quarter, aligning with this clinical progression dynamic.
Capital expenditures remained minimal at $60K in Q1 FY2026, versus $0 in Q1 FY2025. This confirms the company’s pre-commercial posture: no meaningful infrastructure or long-term asset investment is occurring. Instead, resources are fully allocated toward clinical execution — consistent with management’s stated intent to substantially increase research and development expenses for the foreseeable future. Free cash flow, defined as net cash provided by operating activities less capital expenditures, was -$37.6M.
Management states that, based on current operating plans, existing cash, cash equivalents, and marketable securities will be sufficient to fund operations and capital expenditure requirements into the first half of 2029. This outlook rests on disciplined capital allocation and the absence of commercial infrastructure spend. It also reflects an expectation that general and administrative expenses will increase over time — not for commercial readiness today, but to support expanded research and development activities. The company continues to operate without revenue, and its financial trajectory remains tightly coupled to clinical milestones and external financing execution.